Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Key Takeaways
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
CROWN: A Randomized Global Phase 3 Study
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Current Post Hoc Analyses at 5 Years
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
At 60.2 Months of Median Follow-Up, Median PFS by Investigator Was Still Not Reached With Lorlatinib
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
PFS Benefit With Lorlatinib Was Observed Across Patient Subgroups
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Lorlatinib Showed Superior PFS Benefit Irrespective of Presence or Absence of Baseline Brain Metastases
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Time to IC Progression by Investigator Assessment Was Longer With Lorlatinib (ITT Population)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Time to IC Progression Was Longer With Lorlatinib in Presence or Absence of Baseline Brain Metastases
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Safety Profile of Lorlatinib Was Consistent With That Observed in Prior Analyses
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Dose Reduction Did Not Impact Efficacy of Lorlatinib in Patients Who Had Dose Reduction in the First 16 Weeks
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Lorlatinib Treatment Benefited Patients With Poor Prognostic Biomarkers
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Emerging New ALK Mutations Were Not Detected in ctDNA Collected at the End of Lorlatinib Treatment
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
Slide 15
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
The authors would like to thank the participating patients and their families, investigators, sub-investigators, research nurses, study coordinators, and operations staff
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.